Our finding that IRF4 suppresses the CD22 expression is intriguing, as IRF4 has been implicated in the pathogenesis of CLL by genome-wide association studies (39, 48, 49) and driver mutation studies (27, 40, 50, 51). This evidence concerns the gene IRF4 and B-cell chronic lymphocytic leukemia.